7D Surgical Expands Spine and Cranial Technology Offering

7D Surgical announced today important additions to its cranial and spinal product lines. The company has received both 510(k) clearance from the U.S. Food and Drug Administration (FDA) and a medical device license from Health Canada for its Cranial Biopsy Kit, which allows neurosurgeons to use image guidance to accurately target brain lesions during needle biopsy procedures.

In their effort to support a wide range of surgical instruments, 7D Surgical is also announcing the commercial release of its Universal Tracking Kit which spine surgeons can use to track and visualize almost any rigid surgical instrument on the MvIGS system, including third-party vendor taps and screwdrivers.

“7D Surgical has successfully transitioned from a start-up organization to a growth company, having launched more than 33 MvIGS programs since our full commercial release a little over a year ago. We are very proud of our team for commercializing these latest products in the spine and cranial markets,” said Beau Standish, CEO of 7D Surgical. “2020 will be another break out year for our Machine-Vision innovations and continued North American and international expansion.”

The 7D Surgical MvIGS system utilizes completely new camera-based technology and machine vision algorithms to eliminate the long-standing frustrations with legacy surgical navigational platforms. The system uses only visible light, eliminating the patient and staff exposure to intraoperative radiation which is common with older technologies. This results in a nearly instantaneous patient registration in almost any surgical position.

“We have completed more than 1,500 clinical cases with the 7D Surgical System and the feedback from our surgeon users has been tremendous.  I am excited to offer these new technologies to our customer base which expands the functionality of the MvIGS system while maintaining our clear advantages in speed and reduced radiation exposure to operating room staff and patients,” said Brian Stuart, Vice-President of Sales & Marketing at 7D Surgical.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version